Ignite Creation Date:
2024-05-05 @ 4:41 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00295178
Status:
COMPLETED
Last Update Posted:
2017-09-07
First Post:
2006-02-21
Brief Title:
Study Comparing CUBICIN Daptomycin for Injection With Vancomycin in Cellulitis or Erysipelas
Sponsor:
Cubist Pharmaceuticals LLC a subsidiary of Merck Co Inc Rahway New Jersey USA
Organization:
Cubist Pharmaceuticals LLC a subsidiary of Merck Co Inc Rahway New Jersey USA
Study Overview
Official Title:
A Multicenter Randomized Study Comparing CUBICIN Daptomycin for Injection With Vancomycin in the Treatment of Cellulitis or Erysipelas
Status:
COMPLETED
Status Verified Date:
2017-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to investigate the difference in speed and degree of symptom resolution between daptomycin and vancomycin in subjects treated for cellulitis or erysipelas by evaluation of the following parameters
Time to erythema margin cessation to progress
Time to defervescence
Time to hospital discharge following relief of the presenting cellulitis or erysipelas
Degree of improvement of the following signs and symptom of cellulitis or erysipelas including
Degree of improvement of cellulitis-related pain and swelling as reported by subjects
Additionally the difference in frequency of Adverse Events between daptomycin and vancomycin will be described
Time to erythema margin cessation to progress
Time to defervescence
Time to hospital discharge following relief of the presenting cellulitis or erysipelas
Degree of improvement of the following signs and symptom of cellulitis or erysipelas including
Degree of improvement of cellulitis-related pain and swelling as reported by subjects
Additionally the difference in frequency of Adverse Events between daptomycin and vancomycin will be described
Detailed Description:
same as above
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| DAP-4CELL-05-02 | OTHER | Cubist | None |